Madrigal Pharmaceuticals is a biopharmaceutical company that develops and commercializes therapies for liver and metabolic diseases, including its treatment for nonalcoholic steatohepatitis (NASH/MASH).
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|---|---|---|---|---|
| Bridgewater | 55 | New buy | 53,627 | $27,025,863 | 0.1% |
| Louis Bacon / Moore | 52 | New buy | 5,561 | $2,802,522 | 0.1% |
| Paul Tudor Jones / Tudor | 61 | Added +24% | 14,300 | $7,206,628 | 0.0% |
| Steve Cohen / Point72 | 75 | Trimmed -98% | 3,400 | $1,713,464 | 0.0% |
| Filed | Insider | Role | Shares | Value | |
|---|---|---|---|---|---|
| 2026-11-06 | BAKER BROS. ADVISORS LP | director | 91,806 | $35,023,032 | Form 4 |
Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-11-17.